Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 22.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 28.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 22.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 16.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 10.2 and incorporated herein by reference. Item 5.02. Departure of Directors or Certain Officers; Election of Director |
| 15.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 03.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Section 13(a) of the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 15.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ndment”) amends the information disclosed under Item 5.02 of the Current Report on Form 8-K filed on March 12, 2024 (the |
| 12.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 16.01.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | the Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain |
| 15.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain O |
| 26.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. o Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Of |
Stammdaten
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Unternehmen & Branche
| Name | Cencora, Inc. |
|---|---|
| Ticker | COR |
| CIK | 0001140859 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Distribution |
| SIC | 5122 · Wholesale-Drugs, Proprietaries & Druggists' Sundries |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 60,71 Mrd. USD |
| Beta | 0,72 |
| Dividendenrendite | 2,30 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | 85,932,016,000 | 559,647,000 | 2.87 | 78,361,214,000 | 1,908,328,000 |
| 2025-09-30 | 10-K | 321,332,819,000 | 1,554,169,000 | 7.96 | 76,590,112,000 | 1,508,019,000 |
| 2025-06-30 | 10-Q | 80,663,532,000 | 687,402,000 | 3.52 | 73,956,905,000 | 1,980,193,000 |
| 2025-03-31 | 10-Q | 75,453,673,000 | 717,871,000 | 3.68 | 71,193,874,000 | 1,012,837,000 |
| 2024-12-31 | 10-Q | 81,487,060,000 | 488,600,000 | 2.50 | 69,054,314,000 | 226,580,000 |
| 2024-09-30 | 10-K | 293,958,599,000 | 1,509,120,000 | 7.53 | 67,101,667,000 | 645,938,000 |
| 2024-06-30 | 10-Q | 74,241,353,000 | 483,463,000 | 2.42 | 66,772,423,000 | 925,209,000 |
| 2024-03-31 | 10-Q | 68,414,307,000 | 420,775,000 | 2.09 | 63,868,046,000 | 1,083,142,000 |
| 2023-12-31 | 10-Q | 72,252,833,000 | 601,500,000 | 2.98 | 64,690,297,000 | 911,703,000 |
| 2023-09-30 | 10-K | 262,173,411,000 | 1,745,293,000 | 8.53 | 62,558,746,000 | 522,003,000 |
| 2023-06-30 | 10-Q | 66,947,043,000 | 479,581,000 | 2.35 | 61,177,196,000 | 686,018,000 |
| 2023-03-31 | 10-Q | 63,457,205,000 | 435,402,000 | 2.13 | 58,766,183,000 | 281,686,000 |
| 2022-12-31 | 10-Q | 62,846,832,000 | 479,745,000 | 2.33 | 57,906,893,000 | -178,131,000 |
| 2022-09-30 | 10-K | 238,587,006,000 | 1,698,820,000 | 8.04 | 56,560,616,000 | -211,559,000 |
| 2022-06-30 | 10-Q | 60,064,601,000 | 406,964,000 | 1.92 | 57,173,630,000 | 224,299,000 |
| 2022-03-31 | 10-Q | 57,719,446,000 | 548,014,000 | 2.59 | 57,308,153,000 | 550,309,000 |
| 2021-12-31 | 10-Q | 59,628,810,000 | 449,105,000 | 2.13 | 57,577,564,000 | 241,546,000 |
| 2021-09-30 | 10-K | 213,988,843,000 | 1,539,932,000 | 7.39 | 57,337,805,000 | 223,354,000 |
| 2021-06-30 | 10-Q | 53,405,695,000 | 292,122,000 | 1.40 | 55,930,936,000 | 37,962,000 |
| 2021-03-31 | 10-Q | 49,154,171,000 | 435,267,000 | 2.10 | 47,003,250,000 | -281,756,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-20 | Mauch Robert P. | Director, Officer, President & CEO | Open Market Sale | -3,762 | 358.94 | -1,350,332.28 | -66,2% | |
| 2026-02-18 | Mauch Robert P. | Director, Officer, President & CEO | Open Market Sale | -1,333 | 359.46 | -479,160.18 | -23,5% | |
| 2026-01-20 | Mauch Robert P. | Director, Officer, President & CEO | Open Market Sale | -5,096 | 354.73 | -1,807,704.08 | -88,6% | |
| 2025-12-19 | Campbell Elizabeth S | Officer, Executive Vice President | Open Market Sale | -3,351 | 342.10 | -1,146,377.10 | -56,2% | |
| 2025-12-19 | Battaglia Silvana | Officer, Executive Vice President | Open Market Sale | -1,677 | 345.00 | -578,565.00 | -28,3% | |
| 2025-12-18 | Mauch Robert P. | Director, Officer, President & CEO | Open Market Sale | -5,096 | 343.45 | -1,750,221.20 | -85,8% | |
| 2025-12-17 | Krikorian Lazarus | Officer, SVP & Chief Accounting Officer | Open Market Sale | -4,031 | 343.24 | -1,383,580.29 | -67,8% | |
| 2025-11-18 | Mauch Robert P. | Director, Officer, President & CEO | Open Market Sale | -5,096 | 366.64 | -1,868,397.44 | -91,5% | |
| 2025-10-20 | Mauch Robert P. | Director, Officer, President & CEO | Open Market Sale | -5,097 | 326.80 | -1,665,699.60 | -81,6% | |
| 2025-10-01 | Campbell Elizabeth S | Officer, Executive Vice President | Open Market Sale | -1,886 | 313.28 | -590,846.08 | -29,0% | |
| 2025-09-18 | Mauch Robert P. | Director, Officer, President & CEO | Open Market Sale | -5,097 | 290.00 | -1,478,130.00 | -72,4% | |
| 2025-09-16 | COLLIS STEVEN H | Director, Officer, Executive Chairman | Open Market Sale | -31,350 | 289.86 | -9,087,142.35 | -445,3% | |
| 2025-08-19 | COLLIS STEVEN H | Director, Officer, Executive Chairman | Open Market Sale | -14,579 | 289.98 | -4,227,618.42 | -207,1% | |
| 2025-08-18 | Mauch Robert P. | Director, Officer, President & CEO | Open Market Sale | -4,968 | 293.53 | -1,458,257.04 | -71,5% | |
| 2025-07-22 | COLLIS STEVEN H | Director, Officer, Executive Chairman | Open Market Sale | -14,578 | 292.67 | -4,266,543.26 | -209,1% | |
| 2025-07-18 | Mauch Robert P. | Director, Officer, President & CEO | Open Market Sale | -4,968 | 294.11 | -1,461,138.48 | -71,6% | |
| 2025-06-24 | COLLIS STEVEN H | Director, Officer, Executive Chairman | Open Market Sale | -14,579 | 292.62 | -4,266,106.98 | -209,0% | |
| 2025-06-18 | Battaglia Silvana | Officer, Executive Vice President | Open Market Sale | -4,077 | 297.41 | -1,212,520.19 | -59,4% | |
| 2025-06-18 | Mauch Robert P. | Director, Officer, President & CEO | Open Market Sale | -4,969 | 295.30 | -1,467,345.70 | -71,9% | |
| 2025-05-29 | Krikorian Lazarus | Officer, SVP & Chief Accounting Officer | Open Market Sale | -8 | 289.06 | -2,312.48 | -0,1% | |
| 2025-05-29 | Krikorian Lazarus | Officer, SVP & Chief Accounting Officer | Open Market Sale | -2,992 | 288.96 | -864,568.32 | -42,4% | |
| 2025-05-20 | COLLIS STEVEN H | Director, Officer, Executive Chairman | Open Market Sale | -14,578 | 293.84 | -4,283,599.52 | -209,9% | |
| 2025-05-19 | Mauch Robert P. | Director, Officer, President & CEO | Open Market Sale | -4,969 | 291.43 | -1,448,115.67 | -71,0% | |
| 2025-05-14 | GREENBERG LON R | Director | Open Market Sale | -3,000 | 279.05 | -837,150.00 | -41,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.